Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2024; 15(2): 178-194
Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.178
Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.178
Updates on management of gliomas in the molecular age
Ali Ahmed Mohamed, Steven Faragalla, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, United States
Rakan Alshaibi, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, United States
Youssef Mohamed, College of Osteopathic Medicine, Kansas City University, Joplin, MO 64804, United States
Brandon Lucke-Wold, Department of Neurosurgery, University of Florida, Gainesville, FL 32611, United States
Author contributions: Mohamed AA, and Lucke-Wold B designed the research study; Mohamed AA, Alshaibi R, Faragalla S, Mohamed Y and Lucke-Wold B performed the research and analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Brandon Lucke-Wold, MD, PhD, Neurosurgeon, Researcher, Department of Neurosurgery, University of Florida, No. 1505 SW Archer Rd, Gainesville, FL 32611, United States. brandon.lucke-wold@neurosurgery.ufl.edu
Received: October 28, 2023
Peer-review started: October 28, 2023
First decision: December 29, 2023
Revised: January 6, 2024
Accepted: January 25, 2024
Article in press: January 25, 2024
Published online: February 24, 2024
Processing time: 114 Days and 16.9 Hours
Peer-review started: October 28, 2023
First decision: December 29, 2023
Revised: January 6, 2024
Accepted: January 25, 2024
Article in press: January 25, 2024
Published online: February 24, 2024
Processing time: 114 Days and 16.9 Hours
Core Tip
Core Tip: Gliomas are primary brain tumors derived from glial cells of the central nervous system, afflicting both adults and children. This review article explores the therapeutic modalities employed for both adult and pediatric gliomas in the context of their molecular classification. Gliomas are classified by World Health Organization using a grading system grade 1 to 4 differentiating the grades by the gliomas attributes such as progression. The current trident approach to glioma treatment is surgery, radiotherapy, and chemotherapy. Pediatric cases are more nuanced, creating a more challenging approach to treating pediatric gliomas compared to their adult counterpart.